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The objective of this work was to study the coating process of nifedipine extended release pellets using Opadry and Opadry II, in a
fluid bed coater with a Wurster insert. The coating process was studied using a complete experimental design of two factors at two
levels for each polymer. The variables studied were the inlet air temperature and the coating suspension flow rate. The agglomerate
fraction and coating efficiency were the analyzed response variables. The air temperature was the variable that most influenced
the coating efficiency for both polymers. In addition, a study of the dissolution profiles of coated and uncoated pellets using 0.5%
sodium lauryl sulfate in simulated gastric fluid without enzymes (pH 1.2) was conducted. The results showed a prolonged release
profile for the coated and uncoated pellets that was very similar to the standards established by the U.S. Pharmacopoeia. The drug
content and the release profiles were not significantly affected by storage at 40∘C and 75% relative humidity. However, when exposed
to direct sunlight and fluorescent light (light from fluorescent bulbs), the coated pellets lost only 5% of the drug content, while the
uncoated ones lost more than 35%; furthermore, the dissolution profile of the uncoated pellets was faster.
1. Introduction
The administration of drugs by oral dosage is the most
typical, comfortable, and convenient way to release an active
substance in an organism. Among the various pharmaceu-
tical forms in which active substance release systems can be
designed for oral use, pellets have attracted increasing interest
due to several technological and therapeutic advantages [1–
4]. Pellets have excellent flow properties, mainly due to
their spherical shape, narrow particle size distribution, and
surface susceptibility to film coating for the purpose of enteric
protection or extended release.
The technique used to manufacture pellets is extrusion
and spheronization. This process was first reported for use
as a pharmaceutical application by two classic papers in
1970 [1, 5]. Although the extrusion/spheronization technique
creates spherical granules as a product, it differs from the
granulation technique concerning the wet weight treatment
of the fine powders, as well in as the equipment used.
The extrusion/spheronization technique is composed of four
unit operations: granulation, extrusion, spheronization, and
drying.
The pellets are ideal for the application of coatings due
to their spherical shape. The film coating application for
pharmaceutical use may be chosen for functional or esthetic
reasons. The functional objective of film coating is to form
a barrier that protects the pellets from the environmental
conditions and/or to modify the drug release profile.
Fluidized beds are widely used in the pharmaceutical
industry for coating solid particles such as pellets, granules,
and powders. Initially, the particles are fluidized by hot air,
and the coating solution or suspension is sprayed over the
particles. Due to the hot air, the solvent evaporates and
forms a solid film that surrounds the core material. The
main challenge of this process is to form a uniform and
continuous film coating on the pellet surface.The complexity
lies in the large number of variables involved in the process,
which makes studying this coating process relevant to the
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pharmaceutical industry [6]. The Wurster apparatus [7] is
considered the most useful equipment for small-particle film
coating [8].
Teunou and Poncelet [9] conducted a review of coating in
fluidized beds and showed that the Wurster fluidized bed is
the most suitable system for particle coating. They described
the coating process in fluid bed with a Wurster insert and
showed that to achieve an excellent coating, the particlesmust
be dry during the ascent path because agglomeration will
occur if the particles become wet in the annular region. This
agglomeration occurs because the particles in the annular
region are very close to each other, and the air velocity in this
region is very low compared with the velocity in the region of
the inner tube.
Albanez et al. [10] studied the process of coating
diclofenac sodium pellets produced by extrusion/spheron-
ization with an enteric release polymer (Acryl-Eze MP)
in a Wurster fluidized bed. They studied the influence of
two process variables: the inlet air temperature and the
suspension flow rate. The evaluated responses were the
efficiency of the coating process and the agglomeration index.
In all tests, the coating efficiency exceeded 70%. It was
concluded that both the inlet air temperature and suspension
flow rate significantly (95% confidence level) influenced the
coating efficiency and the agglomeration index. Only the
interaction between the variables had no influence on the
responses analyzed. A higher suspension flow rate improved
the coating efficiency; however, it favored agglomeration. On
the other hand, a higher inlet air temperature also led to
agglomeration,whichwas not expected andmay be explained
by the influence of temperature on the adhesion of the film
coating. The drug content and the release profiles were not
significantly affected by storage at 40∘C and 75% relative
humidity.
Currently, the amount of commercially available poly-
meric suspensions and the variety of different required
release profiles are very large. Polymeric suspensions are very
well accepted by the pharmaceutical industry because the
suspensions are easy to prepare and are of low cost. Among
commercialized suspensions, aqueous forms are preferred
because they cause less damage to the environment and do
not pose poisoning risks.
Nifedipine is an active ingredient that is poorly soluble in
water and is widely used as a calcium-blocking agent whose
efficacy and tolerability have been demonstrated in numerous
studies [11].When exposed to daylight or certain wavelengths
of artificial light, nifedipine is converted to the derivative
nitrosophenylpyridine. The exposure of nifedipine to UV
light leads to the formation of the derivative nitrophenylpyri-
dine [12]. The pharmacokinetics and pharmacodynamics
of nifedipine have been characterized using several drug
formulations intended for both oral and parenteral use. It has
been shown that the fast increase of nifedipine concentration
in plasma results in acceleration of the heart rate and side
effects [13–15]. Therefore, modified release formulations of
nifedipine are the preferred therapeutic choices.
Due to its short half-life in vivo, immediate release
doses of nifedipine should be given three times a day [16].
This therapeutic regime causes fluctuations in plasma levels,
which are responsible for side effects. For this reason, it is
appropriate to develop controlled release formulations that
promote adherence to treatment and reduce undesirable
effects [16, 17].
The development of controlled release forms is hampered
by the low solubility of the molecule, which affects its
absorption rate. Measures such as particle size reduction and
polymer solid dispersion [16, 18] have been proposed as ways
to increase the drug’s bioavailability.
Considering all the above-mentioned advantages of mul-
tiparticulate systems and the need to protect nifedipine from
light exposure, the purpose of this work was to develop
nifedipine extended release multiparticulates produced by
the extrusion/spheronization process [19] and coat them
with different commercial powders (Opadry and Opadry II).
These polymers were chosen because they contain titanium
dioxide in their formulation and can protect the micro-
granules from light exposure. The influence of the inlet air
temperature and the suspension flow rate on the coating
process was evaluated, and the surface responses to coating
efficiency and the agglomerate fractionwere investigated.The
drug release profile is in accord with that established in the
United States Pharmacopeia [12].
2. Materials and Methods
2.1. Chemicals. Nifedipine was manufactured by Asmidhi
Labs (India). Microcrystalline cellulose (MCC) 101, the main
diluent in pellet manufacture, was obtained from Mingtai
Chemical (Taoyuan Hsien, Taiwan). Lactose, used as a dilu-
ent, and polyvinylpyrrolidone (PVP-K30), used as a binder,
were manufactured by Valdequı´mica Produtos Quı´micos
Ltda (Brazil). Croscarmellose sodium manufactured by
Amishi Drugs and Chemicals (Ahmedabad, Gujarat, India)
was used as a disintegrant. Polyethylene glycol (PEG4000),
used as a plasticizer and a lubricant, was manufactured by
Valdequı´mica Produtos Quı´micos Ltda (Brazil). Methocel was
manufactured by Colorcon (UK); it was used as a binder
and was also added in a 1% w/w aqueous solution as the
granulation liquid. Silicon dioxide was used as an adsorbent;
it wasmanufactured by Longyan Shenghe Trading (German).
The polymers used to coat the pellets were Opadry and
Opadry II, which were manufactured by Colorcon (Dartford,
Kent, UK). Opadry contains mostly hydroxypropyl methyl-
cellulose, while Opadry II contains mostly polyvinyl alcohol.
2.2. Equipment. The blending and granulation were per-
formed in a planetary mixer. To extrude the dough, a roller
extruder (model EX50, Zelus, Sa˜o Paulo, Brazil) with a
1.0mm screen was used at 50 rpm. For the spheronization
step following the extrusion, a spheronizer was used (model
ES-015, Zelus, Sao Paulo, Brazil) with a rotation velocity
of 900 rpm and perpendicular-type spheronization plate
grooves with a diameter of 23 cm. An oven with forced air
circulation and temperature control (model 420-4D, Nova
E´tica, Sa˜o Paulo, Brazil) was used to dry the pellets. A screen
pack with steel screens with openings between 0.425mm
BioMed Research International 3
Figure 1: Schematic representation of the Wurster process.
and 1.40mm was used for particle size classification of the
pellets. A UV/VIS spectrophotometer (Cary, Varian, USA)
was used to determine the drug content of the pellets and the
amount of released drug in the in vitro dissolution tests. A
scanning electron microscope (LEO 440, Campinas, Brazil)
was used for the morphological analysis of the pellets. In
the dissolution tests, a dissolver (model 299, Nova E´tica, Sa˜o
Paulo, Brazil) with 6 tanks, eachwith a capacity of 900mLand
temperature and rotation control, was used. The film coating
was performed in a fluid bed coater with a Wurster insert,
(model R-060, by Zelus, Sa˜o Paulo, Brazil).
2.3. Preparation of Extended Release Pellets. The pellets were
prepared by the extrusion/spheronization process. The mix-
ing of the powders and addition of a 1% w/w methanol
aqueous solution were performed in a planetary mixer.
The wet mass was passed through a gravity feed lab-scale
radial extruder immediately thereafter. Batches of 270 g
were spheronized at 900 rpm for 40 seconds in a lab-scale
spheronizer. The pellets were dried in a hot air oven at 50∘C
for 24 h. The formulation that was tested is shown in Table 1.
2.4. Film Coating. In the Wurster process, a coating solution
is sprayed on a particle bed moved by an ascending gas
stream. The solution coats the particle in a simultaneous
process of wetting and drying to form a layer with spe-
cific characteristics (Figure 1). The coating experiments were
performed in a fluid bed coater column with a Wurster
insert. The main parts of the fluidized bed used in this
work are a conical base (top diameter: 135mm, bottom
diameter: 77.5mm), an air distribution plate, a draft tube
(height: 153.5mm, inner diameter: 33mm, gap from the
bottom: 7.0mm), a cylindrical glass vessel (inner diameter:
140mm) and a double-fluid nozzle with external mixing
(orifice diameter: 0.7mm).
The airflow rate used in the tests was 1.9 × 10−2 kg/s,
1.15 times higher than that of minimum fluidization, as the
pellets produced were Geldart’s group D (density: 1455 kg/m3
Table 1: Powder mass fractions used in the preparation of extended
release nifedipine pellets.
Material w/w (%)
PEG4000 15.0
Microcrystalline cellulose (MCC) 26.5
Lactose 26.5
Croscarmellose sodium 2.0
Methocel 1.0
PVP-K30 4.0
Nifedipine 25
and medium diameter: 1.04 × 10−3m) particles. The initial
mass of pellets was 350 g, with the size distribution shown
in Table 2. A double-fluid atomizing nozzle with an orifice
of 0.7mm was used. The atomizing air absolute pressure
was 2.0 bar. The coating suspension was kept under agitation
during the coating experiments while being fed with a
peristaltic pump (Provitec, DM7900, Sa˜o Paulo, Brazil). After
the suspension flow was stopped, the pellets remained in the
cyclic bed for 5min. The moisture content of the coated and
uncoated pellets was determined using an oven with forced
air circulation and temperature control until a constant mass
(50∘C for 48 h) was reached.
A two-level factorial design was performed for each
polymer to identify the influential variables in the coating
process, which are inlet air temperature (55 and 65∘C) and
suspension flow rate (5.53 and 6.64 g/min for Opadry; 5.37
and 6.46 g/min for Opadry II), in the coating process. This
design determines which factors have important effects on
the response as well as how the effect of one factor varies
with the level of the other factors.Three runs were performed
at the central point (60∘C and 6.09 g/min for Opadry; 60∘C
and 5.92 g/min, Opadry II). The response variables were the
coating efficiency and the agglomerate fraction, which are
defined as follows.The coating efficiency (𝜂)was calculated by
dividing the actualmass gain by the theoreticalmass gain.The
actual mass gain (𝜑) was determined by weighing the dried
pellets before and after coating, and the theoretical mass gain
is the gain that would have been achieved if all of the solid
material in the suspension had adhered to the surface. The
agglomerate fraction (𝑓agg) is given by the mass of agglom-
erates in relation to the total mass of coated pellets. Particles
larger than 1.40mmwere considered agglomerates. Statistical
analyses were performed using Statistica 10.0 software. The
analysis of variance and the graph of the values predicted by
observation were analyzed, and the response surfaces for the
coating efficiency and agglomerate fraction were traced.
As shown in Table 1, the extended release pellets pro-
duced were coated with the aim of protecting them from
exposure to light without changing the dissolution profile
because the polymers used are for immediate release.The the-
oretical weight gain in the coating process was approximately
11%, as shown in Table 3.
2.5. Drug Content. The drug content of both coated and
uncoated pellets was determined by powdering 300mg of the
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Table 2: Size distribution of the pellets used in the coating experi-
ments.
Size range (mm) Opadry II Opadry
𝑀 (g) % 𝑀 (g) %
1.18 < 𝑑 < 1.40 67 19 82 24
1.00 < 𝑑 < 1.18 154 44 146 42
0.85 < 𝑑 < 1.00 95 27 87 25
0.71 < 𝑑 < 0.85 34 10 35 10
Total 350 100 350 100
Table 3: Theoretical weight gain in the coating process.
Test Opadry II Opadry
𝜙 (%) 𝜙 (%)
1 7.4 10.5
2 10.8 11.9
3 10.8 11.7
4 10.9 11.7
5(C) 11.4 11.4
6(C) 11.2 9.3
7(C) 11.0 10.6
pellets.Thedrugwas then extractedwith amethanol solution.
The filtered extract was assayed spectrophotometrically at a
wavelength of 350 nm (according to graphs of the absorbance
spectrum and information obtained from the USP XXXII).
The drug content determination was performed in triplicate,
and all tests were performed in the absence of light and using
glassware wrapped in aluminum foil.
2.6. Dissolution Tests. Both uncoated and coated pellets
were subjected to dissolution studies to verify the extended
release profile. In this analysis, 0.5% sodium lauryl sulfate
in simulated gastric fluid without enzymes (pH 1.2) at 37∘C
was used as the dissolution medium for 12 h. Apparatus
1 (basket) was used at 100 rpm. Two replicate samples of
approximately 50mg of particles were put in the baskets. A
sample of 5mL from each vessel was filtered using a 0.45 𝜇m
filter (Sartorius,Minisart RC25), and the dissolved amount of
nifedipine was assayed spectrophotometrically at wavelength
of 238 nm (according to graphs of the absorbance spectrum
and information obtained from theUSPXXXII).The rotation
speed was 100 rpm.The dissolution tests were performed in a
6-vessel dissolver (Nova E´tica, Brazil).
2.7. The Coating Suspensions. Opadry and Opadry II are
fully formulated dry coating systems that are dispersible in
water and use (hydroxypropyl methylcellulose) HPMC and
(polyvinyl alcohol) PVA, respectively, in their formulations.
These polymers contain titanium dioxide in their formula-
tions, which may protect the microgranules from exposure
to light, thus avoiding drug degradation. The suspension
containing Opadry was prepared with 12% w/w of powder
dispersed in water, and the suspension containing Opadry II
was prepared with 20% w/w powder in water. The rheology
of the coating suspensions was determined using a Brookfield
Rheometer.
2.8. Scanning Electron Microscopy (SEM). The particles were
subjected to scanning electron microscopy with an LEO
440 Stereoscan microscope. This analysis aimed to visualize
the surface morphology. The samples were mounted onto
circular aluminum stubs with double-sided carbon tape and
then coated with platinum.
2.9. Storage Stability. For a commercial product, the guaran-
tee of stability is vital for its safety and efficacy during storage
and use. In this study, coated and uncoated pellets were stored
under stress conditions of 40∘C and 75% relative humidity.
Thedrug content and dissolution profilesweremeasured after
30, 60, 90, and 180 days.
For the photostability study, the samples were exposed to
a fluorescent light and daylight for ten days.The drug content
and dissolution profiles were measured.
3. Results and Discussion
3.1. Coating Suspension Rheology. Thepolymeric suspensions
were prepared at the maximum concentration following
the manufacturer’s indications: 12% w/w Opadry and 20%
w/w Opadry II. For both coating suspensions (Opadry
and Opadry II), the shear stress varies linearly with the
deformation rate; in other words, the shear stress is directly
proportional to the velocity gradient. Therefore, the two
polymeric suspensions, Opadry II and Opadry behave as in
themodel proposed by IsaacNewton and are thusNewtonian
fluids. The experimental curves for shear stress and viscosity
are shown in Figure 2 and Table 4, respectively.
The viscosity of the polymeric suspension of Opadry II
is much lower than that of the Opadry suspension, although
its solid content is higher. The low viscosity of Opadry II
results in excellent and uniform droplet size, improving its
performance in the coating process when compared with that
of Opadry, which presented higher viscosity values (Table 4).
3.2. Uncoated Pellet Dissolution Studies. Dissolution tests
were performed with the uncoated pellets according to the
methods described in Section 2.6. As shown in Figure 3 and
Table 5, the uncoated pellets presented an extended release
profile that is similar to the United States Pharmacopeia
[12] standards. The drug release profile for the nifedipine
pellets was controlled by varying the ratio of microcrystalline
cellulose, croscarmellose sodium, and lactose in the pellet
formulation combined with the use of the controlled release
polymers, as shown in Table 1.
3.3. Coating Process. Coating experiments were performed
for each polymer (Opadry and Opadry II) using a 22 factorial
design. The aim of this analysis was to investigate the
influence of process variables on the coating performance
and was determined by the two response variables 𝜂 and 𝑓agg.
The results for each polymer investigated are presented in
Table 6. The response variable 𝜂 was affected by inlet air
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Figure 2: Experimental curves forshear stress versus deformation
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Figure 3: Dissolution profile of uncoated pellets in 0.5% sodium
lauryl sulfate in simulated gastric fluid without enzymes (pH 1.2).
Table 4: Viscosity values of coating suspensions.
Opadry II Opadry
Test 𝜇 (kg/m⋅s) Test 𝜇 (kg/m⋅s)
A 0.0486 A 0.0735
B 0.0484 B 0.0737
C 0.0488 C 0.0735
Mean 0.0486 ± 0.00014 Mean 0.0736 ± 0.00010
Table 5: Absolute values of the average fraction of nifedipine
released in the in vitro dissolution tests of the pellets and the value
ranges established by the US Pharmacopoeia.
Time (h) Amount dissolved(%), experimental
Amount dissolved
(%), Pharmacopeia
1 27.1 ± 2.5 10–35
4 56.7 ± 2.4 40–67
12 80.5 ± 1.6 Not less than 80
temperature, the interaction between inlet air temperature,
and the suspension flow rate for a 𝑃 value of 0.05, as shown
in the Pareto charts in Figures 4 and 6.The values that appear
above the bars in Figures 4, 5, 6, and 7 are the calculated effects
whose level of significancemust be comparedwith the𝑃 value
of 0.05 [20].
The variable that most influenced the coating efficiency
was the air temperature. The coating performed at higher
temperatures and flow rates (test 2; Table 6) resulted in
improved coating efficiency, and the efficiency of Opadry II
was very close to 100%. The lowest coating efficiency was
obtained at a low air temperature and high flow rate (test
1; Table 6); this occurred because the air temperature was
not sufficient to evaporate the solvent adhered to the pellets,
which increased the agglomerate fraction.
The suspension flow rate was the only factor that signifi-
cantly influenced the agglomerate fraction when the pellets
were coated with a polymeric suspension of Opadry II
(Figure 7). The positive effect of this factor showed that a
higher flow rate resulted in an increased agglomerate fraction,
which is undesirable in the coating process and corroborates
the observations by Albanez et al. [10] in their coating
process study of diclofenac sodium pellets. The reason for
this behavior is that the drying did not occur fast enough
to dry the suspension in the spout region of the bed, and
the wet pellet surface caused the adhesion of the particles. In
addition to the suspension flow rate, the inlet air temperature
also significantly influenced the agglomerate fraction when
the coating process was carried out with the polymeric
suspension of Opadry (Figure 5). The negative effect of inlet
air temperature meant that when the coating process was
carried out at lower air temperatures, a higher agglomerate
fraction resulted. Because drying occurs faster at higher
temperatures, the increase in agglomeration can be explained
by a greater amount of liquid on the surface.
The variance analysis showed that the regression is signif-
icant for the predictive linear models of the coating efficiency
(for both Opadry and Opadry II) and the agglomerate
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Table 6: Influence of process variables on coating performance with the different polymers.
Test 𝑇 𝑉 Opadry II Opadry
𝑓agg (%) 𝜂 (%) 𝑓agg (%) 𝜂 (%)
1 −1 +1 13.9 55.4 32.7 51.5
2 +1 +1 12.2 98.2 14.4 86.7
3 −1 −1 2.8 71.8 13.7 66.1
4 +1 −1 4.8 80.2 2.9 68.1
5(C) 0 0 12.8 82.7 13.3 74.9
6(C) 0 0 11.6 83.2 14.6 77.2
7(C) 0 0 11.4 79.3 16.6 69.8
4.9
4.4
0.5
T by V
T
V
P = 0.05
Figure 4: Pareto chart of effects: coating efficiency, 𝜂-Opadry.
9.4
T by V
T
V
P = 0.05
−8.7
−2.1
Figure 5: Pareto chart of effects: agglomerate fraction, 𝑓agg-Opadry.
5.8
3.9
0.2
T by V
T
V
P = 0.05
Figure 6: Pareto chart of effects: coating efficiency, 𝜂-Opadry II.
T by V
T
V
P = 0.05
12.4
0.2
−2.5
Figure 7: Pareto chart of effects: agglomeration fraction, 𝑓agg-
Opadry II.
fraction (only for Opadry). The response surfaces of the
predictive models for coating efficiency are shown in Figures
8 and 9, and the equations of the linear models are shown
in coded variables in (1) and (2). The response surface of the
predictive model for the agglomerate fraction is shown in
Figure 10, and the equation of the linear models is shown in
coded variables in (3):
𝜂 (𝑇, 𝑉) = 78.690 + 12.800 ⋅ 𝑇 + 8.610 ⋅ 𝑇 ⋅ 𝑉 (1)
𝜂 (𝑇, 𝑉) = 70.610 + 9.293 ⋅ 𝑇 + 8.273 ⋅ 𝑇 ⋅ 𝑉 (2)
𝑓agg (𝑇, 𝑉) = 15.464 − 7.265 ⋅ 𝑇 + 7.625 ⋅ 𝑉. (3)
The response surfaces indicate that elevated inlet air tem-
perature and flow rate increase the efficiency of the coating
process; however, an elevated suspension flow rate increases
the agglomerate fraction during the coating process.
The suspension of Opadry II was favorable for increased
coating efficiency, although its solid content was greater than
that of the suspension of Opadry, because the suspension
containing Opadry II had a much lower viscosity than the
suspension containingOpadry; it also contained talc as a sur-
factant agent, which reduced the surface tension, promoting
the spread of the suspension over the particle surface and
improving its wettability. Moreover, the coating time with the
Opadry II polymeric suspension is significantly lower than
the process time of the Opadry polymeric suspension for the
same mass gain.
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Figure 10: Response surface for the agglomerate fraction of Opadry.
The amount of the suspensions sprayed onto the pellets
was sufficient for theoretical mass gains of 11%.This value was
recommended by the manufacturer. The actual mass gains
from the tests are shown in Table 7.
The coated pellets were submitted to in vitro dissolution
tests. The results are shown in Figures 11 and 12. The coated
pellets presented release profiles similar to those of uncoated
pellets.This result was expected because the polymers applied
in the coating process are immediate release, not modified
release. Therefore, the coated pellets presented extended
release profiles that were similar to those of the United States
Pharmacopeia [12] standards (Table 5).
The uncoated pellets have a rough, irregular surface, as
shown in Figures 13 and 14. When the polymer coats the
granule, the surface is smoothened and rounded, with no
visible cracks. As a consequence, the film creates a barrier
between the environment and the pellet. The surface of a
coated particle is shown in Figures 15 and 16. In Figure 17,
coating layers of approximately 14 𝜇m and 10 𝜇m are visible
on pellets coated with Opadry II and Opadry, respectively.
These pellets were obtainedwith a 9.43% and 8.54%mass gain
(test 5 (C)—Table 7) using polymeric suspensions of Opadry
II and Opadry, respectively.
3.4. Stability. The accelerated stability tests (40∘C, 75% rh)
were performed as described in Section 2.9. In Figures 18, 19,
and 20 the dissolution profiles of the uncoated and coated
pellets for the 180 study days can be observed. The coated
and uncoated pellets remained stable. The amounts of drug
released at 30, 60, 90, and 180 days were very similar to
the amount released at the beginning (day 0), as discussed
8 BioMed Research International
0
10
20
30
40
50
60
70
80
90
0 2 4 6 8 10 12
D
ru
g 
re
le
as
e (
%
)
Time (h)
Test 1
Test 2
Test 3
Test 4
Test 5 (C)
Test 6 (C)
Test 7 (C)
Uncoated
Figure 11: Dissolution of pellets coated with Opadry II.
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Figure 12: Dissolution of pellets coated with Opadry.
Table 7: Evaluation of coating experiments.
Test 𝑇 𝑉 Opadry II Opadry
𝜑 (%) 𝜑 (%)
1 −1 +1 4.1 5.4
2 +1 +1 10.6 10.3
3 −1 −1 7.8 7.7
4 +1 −1 8.8 7.9
5(C) 0 0 9.4 8.5
6(C) 0 0 9.3 7.2
7(C) 0 0 8.8 7.4
in Section 3.2. Furthermore, the drug content of the pellets
remained constant during this period. These results indicate
that during the period of 180 days, there was not sufficient
physical and chemical degradation in the pellet matrix to
Figure 13: Uncoated pellets (150x).
Figure 14: Uncoated pellets (1500x).
(a)
(b)
Figure 15: Coated pellets (150x): (a) Opadry II; (b) Opadry.
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Figure 16: Coated pellets (1500x): (a) Opadry II; (b) Opadry.
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Figure 17: Coated pellets (1500x).
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Figure 18: Dissolution profiles of uncoated pellets before and after
storage under stress conditions.
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Figure 19: Dissolution profiles of pellets coated with Opadry II (test
5 (C)) before and after storage under stress conditions.
modify the drug dissolution profile. However, when the
pellets were subjected to light stress conditions, only the
drug content and dissolution profile of the uncoated pellets
were changed, as shown in Table 8 and Figure 21. In the
uncoated pellets, the nifedipine degraded at a ratemuch faster
than in the pellets coated with either of the two polymeric
suspensions. After 10 days of light exposure, the coated
pellets had lost only approximately 5% of the drug content,
while the uncoated pellets had lost 40%. Figure 22 shows the
fraction of drug content lost from the coated and uncoated
pellets during the 10 days of light exposure. Therefore, the
coating of nifedipine extended release pellets is necessary to
protect them from light, thereby avoiding drug degradation
and changes in the dissolution profile. The two polymeric
suspensions used for coating the pellets contain titanium
dioxide, which acts as an opacifying agent, protecting the
pellets from exposure to light and increasing their shelf life;
10 BioMed Research International
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Figure 20: Dissolution profiles of pellets coated with Opadry (test 5
(C)) before and after storage under stress conditions.
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Figure 21: Dissolution profiles of uncoated pellets after storage
under light stress conditions.
Table 8: Drug content with storage time under light stress.
Time (days) Drug content of the pellets (%)
Uncoated Opadry II Opadry
0 24.4 ± 0.2 22.4 ± 0.3 22.1 ± 0.1
1 23.4 ± 0.2 21.9 ± 0.3 22.8 ± 0.2
2 22.4 ± 0.5 21.5 ± 0.1 21.6 ± 0.2
3 21.2 ± 0.4 21.4 ± 0.2 21.3 ± 0.3
6 16.6 ± 0.2 21.2 ± 0.2 21.0 ± 0.3
10 14.8 ± 0.1 21.1 ± 0.2 20.9 ± 0.2
this corroborates the reports of Rowe et al. [21] and Rocha
and Taranto [22].
4. Conclusions
The statistical analysis of the coating process showed that
the inlet air temperature and the interaction between the
air temperature and the suspension flow rate influenced the
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Figure 22: Drug content fraction lost after storage under light stress
conditions.
coating efficiency with a 95% confidence level. The variable
that most influenced the coating efficiency was the inlet air
temperature. Higher suspension flow rates resulted in better
coating efficiency but also favored agglomeration, which was
expected. The coating performed at higher temperatures and
flow rates resulted in improved processing efficiency, and the
efficiency of the Opadry II polymer was very close to 100%.
The coating time with the polymeric suspension of Opadry II
was significantly lower compared to the processing time for
the polymeric suspension of Opadry for the same mass gain.
The suspension flow rate was the only factor that significantly
influenced the agglomerate fraction when the pellets were
coated with a polymeric suspension of Opadry II. In addition
to the suspension flow rate, the inlet air temperature also
significantly influenced the agglomerate fraction when the
coating process was carried out with a polymeric suspension
of Opadry. The response surfaces indicate that the path
of maximum slope (higher agglomerate fraction) occurs
when the coating process is carried out at high flow rates
and low air temperatures. The in vitro dissolution studies
showed that the nifedipine release profile was not affected by
the polymeric coatings. However, the photostability studies
showed that the coating of nifedipine extended release pellets
is necessary because the dissolution profile and drug content
were significantly altered for only the uncoated pellets when
they were exposed to light.
Nomenclature
𝜇: Viscosity (Pa ⋅ s)
𝜏: Shear stress (kg/m ⋅ s2)
𝜂: Coating efficiency (%)
𝜑: Actual mass gain (%)
𝜙: Theoretical mass gain (%)
𝑓agg: Agglomerate fraction (%)
𝑑𝑢/𝑑𝑦: Deformation rate (1/s)
𝑉: Flow rate (g/min)
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𝑇: Temperature (∘C)
𝑀: Mass (g).
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